All posts by matthiaswacker

Predicting Nanomedicines

A wide variety of models have been established to predict the performance of nanomedicines for the peroral route of administration, but only a handful for injectables. Liposomal temoporfin has been evaluated in a phase I clinical trial. This investigation was focused on the prediction of the performance of liposomes in humans using preclinical in vitro and in vivo data. Congratulations to our young researcher Laura Jablonka who is responsible for this great accomplishment. Also, it is a prime example for international collaborations by involving researchers from Germany and Singapore…

Best Abstract Award @ AAPS

We were informed that Ge Fiona Gao received the Best Abstract Award for the AAPS Annual Meeting 2019 with her abstract “Elucidating Human Pharmacokinetics of a Subcutaneous Microparticle Depot Formulation: Impact of Drug Formulation, Patient Population and Clinical Setting“. We are proud to have her in our team and wish her a successful visit at the conference in San Antonio, Texas!

Our paper @ Adv Drug Del Rev

Our new article on the challenges associated with market translation of nanotechnology-related products has been accepted by Advanced Drug Delivery Reviews.

The international team of experts has done a great job in providing their expertise. Thanks to you Margareth Marques (USP), Choo Qiuyi (HSA), Mukul Ashtikar (Fraunhofer IME), Thais Correa Rocha (ANVISA) and Susanne Bremer-Hoffmann (EC-JRC).

Expert @ USP

For the next term from 2020 to 2025 I will join the USP Expert Panel on New Advancements in Product Performance Testing. A workshop will take place in December 2019 to share our latest experiences with novel drug release methods. Please check the USP website for further information…